Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Clinical trial NCT04796857 · UNKNOWN

Trial details

NCT number: NCT04796857
Sponsor: Huiqiang Huang
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-GCB/ABC Diffuse Large B-Cell Lymphoma High-grade B-cell Lymphoma Follicular Lymphoma Grade IIIb Transformed Lymphoma EBV-Positive DLBCL, Nos ALK-Positive Anaplastic Large Cell Lymphoma

Start date: 2021-03-31
Primary completion: 2023-03-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.